Canine atopic dermatitis: role of luteolin as new natural treatment

Background: Luteolin has been demonstrated to possess numerous biological effects. However, the effect of luteolin on LPS (Lipopolysaccharides) stimulation in CPEK cells has not been investigated. Hypothesis/Objectives: An in vitro model of atopic canine dermatitis was used to identify the antioxidant effect of luteolin as a new treatment that is capable of improving the conditions of veterinary patients. Methods: CPEK cells were treated with or without luteolin in the presence or absence of LPS. A cell viability assay was performed to test luteolin toxicity and the protective effect of luteolin after LPS stimulation. Additionally, enzyme-linked immunosorbent assay (ELISA) kits were used to detect the levels of IL-33, IL-1β, IL-6, and IL-8. Results: Luteolin was capable to significantly decrease levels expression of IL-33, IL 1β, IL-6, and IL-8. Conclusions and clinical importance: Luteolin could be a new pharmacological treatment for canine atopic dermatitis.